Ibrutinib is a first-in-class oral irreversible inhibitor of BTK (Bruton’s tyrosine kinase) and has been demonstrated to be an effective treatment for chronic lymphocytic leukemia and other B-cell lymphomas (Ahn and Brown, 2021). The gene discussed is BTK; the disease is B-cell non-Hodgkin lymphoma.